FDA authorizes marketing of Medasense’s NOL® (nociception level index) technology through a De Novo grant
/
DateFeb 23 2023
Agency Clearance Paves Way for Commercialization in the United States of First and Only Authorized Device to Measure Pain in Anesthetized Patients Undergoing Surgery RAMAT... Read More →



















